trial

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

NCTId NCT01451736
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 146 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2021-12-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
146 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2011-10
Primary completion
2021-12-01
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
PaliperidoneRisperidone

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
National Institute of Mental Health (NIMH)Collaborator
Janssen, L.P. - Investigator Initiated Studies ProgramCollaborator

Investigators

1
Keith H Nuechterlein, Ph.D.Principal Investigator

Sites

1 total
Los Angeles, United States

Facts & assertions

4 sourced
Enrollment
146
Phase
PHASE4
Primary Completion Date
2021-12-01
Status
COMPLETED
relationships
The graph out of here
drug
Paliperidone
drug
Risperidone
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
National Institute of Mental Health (NIMH)
company
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia (Recent-onset)
indication
Schizophrenia
indication
Psychotic Disorders
indication
investigator
Keith H Nuechterlein, Ph.D.
person